Modern Authentication of Pharmaceuticals Act of 2025
Summary
What This Bill Does
The Modern Authentication of Pharmaceuticals Act changes the Federal Food, Drug, and Cosmetic Act's drug supply chain security rules. For controlled substances in solid oral dosage form manufactured five years after enactment, each dose must include a physical chemical identifier in or on the dose. The bill also updates the definition of product identifier so it can be either the existing standardized graphic and machine-readable carrier or a physical chemical identifier. The practical point is dose-level authentication for controlled substances, which affects pharmaceutical manufacturers, pharmacies, wholesalers, counterfeit-drug investigators, and patients.
Who Benefits and How
Patients using controlled substances benefit if dose-level identifiers reduce counterfeit or diverted pills in the supply chain. Pharmacies benefit from an additional authentication tool for solid oral controlled-substance products. Drug diversion investigators benefit from a physical identifier that can help distinguish legitimate doses from counterfeit products. Technology vendors for pharmaceutical authentication benefit from demand for physical chemical identifier systems.
Who Bears the Burden and How
Controlled-substance manufacturers must add physical chemical identifiers to covered solid oral dosage products after the transition period. Pharmaceutical packaging and formulation teams must redesign products or processes to include identifiers. FDA supply-chain staff must oversee a new product-identifier option in the drug tracing framework. Wholesalers and dispensers may need training and systems to recognize or verify the new identifiers.
Key Provisions
- Requires physical chemical identifiers for covered solid oral dosage controlled substances.
- Provides a five-year manufacturing transition before the identifier requirement applies.
- Amends the product identifier definition to include physical chemical identifiers.
- Strengthens authentication of controlled substances in the pharmaceutical distribution supply chain.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Requires physical chemical identifiers for solid oral dosage controlled substances manufactured after a five-year transition and updates federal drug-supply-chain product identifier rules.
Key Policy Areas
Pharmaceuticals, Drug Supply Chain, Controlled Substances
Primary Purpose
Requires physical chemical identifiers for solid oral dosage controlled substances manufactured after a five-year transition and updates federal drug-supply-chain product identifier rules.
Policy Domains
Resolution provisions
Identified Gains
- Patients using controlled substances
- Pharmacies
- Drug diversion investigators
- Pharmaceutical authentication vendors
Identified Costs
- Controlled-substance manufacturers
- Pharmaceutical formulation teams
- FDA supply-chain staff
- Wholesalers
Sponsors
Legislative Progress
In CommitteeMr. Davis of North Carolina (for himself, Mr. Rutherford, and …
Sponsor introductory remarks on measure. (CR H519)
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology